Abstract

131I is used clinically for therapy, and may be released during nuclear accidents. After the Chernobyl accident papillary thyroid carcinoma incidence increased in children, but not adults. The aims of this study were to compare 131I irradiation-dependent differences in RNA and protein expression in the thyroid and plasma of young and adult rats, and identify potential age-dependent biomarkers for 131I exposure. Twelve young (5 weeks) and twelve adult Sprague Dawley rats (17 weeks) were i.v. injected with 50 kBq 131I (absorbed dose to thyroid = 0.1 Gy), and sixteen unexposed age-matched rats were used as controls. The rats were killed 3–9 months after administration. Microarray analysis was performed using RNA from thyroid samples, while LC–MS/MS analysis was performed on proteins extracted from thyroid tissue and plasma. Canonical pathways, biological functions and upstream regulators were analysed for the identified transcripts and proteins. Distinct age-dependent differences in gene and protein expression were observed. Novel biomarkers for thyroid 131I exposure were identified: (PTH), age-dependent dose response (CA1, FTL1, PVALB (youngsters) and HSPB6 (adults)), thyroid function (Vegfb (adults)). Further validation using clinical samples are needed to explore the role of the identified biomarkers.

Details

Title
Age-related long-term response in rat thyroid tissue and plasma after internal low dose exposure to 131I
Author
Larsson Malin 1 ; Nils-Petter, Rudqvist 2 ; Spetz Johan 3 ; Parris, Toshima Z 4 ; Langen Britta 5 ; Helou Khalil 4 ; Forssell-Aronsson, Eva 6 

 University of Gothenburg, Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582) 
 University of Gothenburg, Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); University of Texas MD Anderson, Department of Thoracic/Head and Neck Medical Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); University of Texas MD Anderson, Department of Immunology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
 University of Gothenburg, Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Harvard T. H. Chan School of Public Health, John B. Little Center for Radiation Sciences, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 University of Gothenburg, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582) 
 University of Gothenburg, Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); UT Southwestern Medical Center, UT Department of Radiation Oncology, Division of Molecular Radiation Biology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121) 
 University of Gothenburg, Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582); Sahlgrenska University Hospital, Department of Medical Physics and Biomedical Engineering, Gothenburg, Sweden (GRID:grid.1649.a) (ISNI:000000009445082X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2626563629
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.